03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Mefoxin 2g° : | |
Type | Medicine Withdrawn |
Originator | B |
Agent | Droguerie de l'Union |
Distributor | Droguerie de l'Union |
Laboratory | MSD |
Manufacturer | Merck Sharp & Dohme BV |
Origin | The Netherlands |
ATC | J01DD01 |
Mefoxin 2g° :
Mefoxin 2g° :
Mefoxin 2g° :
Mefoxin 2g° :
Mefoxin 2g° :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal pain | Not known |
Acute generalised exanthematous pustulosis (AGEP) | Not known |
Agranulocytosis | Not known |
ALT increased | Uncommon |
Anaphylactic reactions | Not known |
Anaphylactic shock | Not known |
Angioedema (Angioneurotic oedema) (Quincke oedema) | Not known |
AST increased | Uncommon |
Blood bilirubin increased | Uncommon |
Bronchospasm | Not known |
Convulsion | Uncommon |
Creatinine increased | Uncommon |
Diarrhoea (Diarrhea) | Uncommon |
Disturbances in consciousness | Not known |
Dizziness | Not known |
Encephalopathy | Not known |
Eosinophilia | Uncommon |
Erythema multiforme | Not known |
Fever | Uncommon |
Function kidney decreased | Uncommon |
Gamma-GT increased | Uncommon |
Haemolytic anemia | Not known |
Headache | Not known |
Hepatic damage | Not known |
Hepatic enzyme increased | Uncommon |
Injection site inflammation | Uncommon |
Injection site pain | Very Common |
Injection site phlebitis | Uncommon |
Injection site thrombophlebitis | Uncommon |
Interstitial nephritis | Not known |
Jarisch-Herxheimer reaction | Uncommon |
Jaundice | Not known |
LDL Increased | Uncommon |
Leucopenia (Leukopenia) | Uncommon |
Lyell Syndrome (Toxic epidermal necrolysis) | Not known |
Movement disorder | Not known |
Nausea | Not known |
Neutropenia | Not known |
Pancytopenia | Not known |
Phosphatase alkaline increased | Uncommon |
Pruritus | Uncommon |
Pseudomembranous colitis | Not known |
Renal failure acute (Acute renal insufficiency) (Kidney failure acute) (Renal insufficiency acute) | Not known |
Skin rash | Uncommon |
Stevens-Johnson syndrome | Not known |
Superinfection | Not known |
Thrombocytopenia (Thrombopenia) | Uncommon |
Urticaria | Uncommon |
Vein inflammation | Not known |
Vomiting | Not known |
NB : Products With Same Indication |
Different Units By MoH Code
Mefoxin 2g° MoH 332 :
Form | Solution for injection |
Packaging | Ampoules |
Package Size | 1x20ml |
Strength | 2g |
Stratum | N/A |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 25063 |
Submission date | 01/01/1981 |
Registration Year | 1981 |
Withdrawn Date | 2006 |
Price Comparison
You have to register to view this info
Drop File